PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF

2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS

(THE "TRANSPARENCY LAW")

GHENT, Belgium, 15 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V. on 14 February 2018.

Van Herk Investments B.V. notified Ablynx that it has downward crossed the 10% threshold on 12 February 2018 and now holds 7,451,158 voting securites of Ablynx, representing 9.93% of the current 75,065,990 outstanding voting rights of Ablynx (versus 10.21% notified previously on 15 January 2018).

The notification contains the following information:

  • - Reason for the notification: acquisition or disposal of voting securities or voting rights

  • - Notification by: a parent undertaking or a controlling person

  • - Persons subject to the notification requirement: Mr. A. van Herk, Van Herk Investments B.V.

  • - Transaction date: 12 February 2018

  • - Threshold that is crossed: 10%

  • - Denominator: 75,065,990

  • - Details of the notification: Van Herk Investments B.V. holds 7,451,158 voting securities of Ablynx

  • - Chain of controlled undertakings through which the holding is effectively being held: Van Herk Investments B.V. is controlled by Mr. A. van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code.

A full version of the transparency notification is available on Ablynx website, under the sectionInvestors.

The articles of the association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development ofNanobodies,proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than45 proprietaryand partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found onwww.ablynx.com.

For more information, please contact:

Ablynx

Dr Edwin Moses CEO t: +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e:edwin.moses@ablynx.comLies Vanneste Director IR t: +32 (0)9 262 0137 m: +32 (0)498 05 35 79 e:lies.vanneste@ablynx.com

@AblynxABLX

Ablynx media relations:

Consilium Strategic Communications Mary-Jane Elliott, Philippa Gardner, Sukaina Virji t: +44 (0)20 3709 5700 e:ablynx@consilium-comms.com

Joele Frank, Wilkinson Brimmer Katcher Dan Katcher or Joseph Sala t: +1 212-355-4449

Ablynx NV published this content on 15 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 February 2018 06:35:06 UTC.

Original documenthttp://hugin.info/137912/R/2168984/835210.pdf

Public permalinkhttp://www.publicnow.com/view/AD581DCF7C8FA97E1F75A49953643958A7015FC4